Penile Cancer Treatment: Surgery, Radiation, Chemotherapy, and Recovery

There is no single penile cancer treatment that fits every man. Your plan depends on the stage of the cancer (how far it has grown and whether it has spread), the grade (how abnormal the cells look under a microscope), exactly where on the penis the tumour sits, how deep it goes, and how much healthy tissue can be safely left behind. Your general health, other medical conditions, and what matters most to you all count too. Two men with the same stage on paper can be offered different plans for good reasons.

The goal your team works toward is straightforward. European Association of Urology guidelines describe the aim as complete removal of the tumour with as much of the penis preserved as possible, without giving up any chance of cure. That balance is the whole conversation. Treatments that save more tissue carry a somewhat higher risk that the cancer comes back in the same place. Treatments that remove more tissue lower that risk but cost more in appearance, sensation, and function. Neither answer is automatically right, which is why guidelines call for a balanced discussion with you rather than a decision made for you.>

Penile cancer is treated by a team, not one doctor. That team usually includes a urologist who specializes in penile cancer, a specialist nurse, a pathologist, a radiologist, a nuclear medicine specialist, a medical oncologist, a radiation oncologist, a reconstructive surgeon, a lymphoedema therapist, a psychologist or counsellor, a sex therapist, and a palliative care clinician for symptom control. Cases are usually reviewed together in a meeting before a plan is finalized.

Types of Treatment for Penile Cancer

Treatment for penile cancer falls into a handful of categories. Surgery is the main treatment for nearly every stage. Radiation therapy can treat the tumour itself, treat the lymph nodes after surgery, or relieve symptoms in advanced disease. Chemotherapy comes in two very different forms: a cream applied to the skin for surface disease, and drugs given into a vein or by mouth that travel through the whole body. Topical creams, laser, and freezing treat precancerous change and very early disease. Immunotherapy and targeted drugs are mostly still being studied in trials.

Most men receive more than one of these. A common pattern is surgery on the tumour, then a separate decision about the lymph nodes in the groin, then sometimes chemotherapy or radiation depending on what the pathologist finds. Treatment given after surgery to lower the chance the cancer returns is called adjuvant therapy. Treatment given before surgery to shrink disease and make an operation possible is called neoadjuvant therapy.

The lymph nodes deserve their own mention here because they drive so much of the plan. Penile cancer spreads in an orderly way, first to the inguinal lymph nodes (small filtering glands in the crease of the groin), then to deeper nodes in the pelvis, and only then to distant places. Node status is the single most important factor in predicting outcomes. That is why so much of penile cancer treatment is about the groin even when the tumour on the penis was small.

Treatment for the tumour and treatment for the nodes are often decided at different times. Your surgeon may remove the tumour first, wait for the full pathology report, and then talk with you about whether the nodes need to be checked or removed. This is normal sequencing, not a delay. Guidelines do recommend completing surgical management of the inguinal and pelvic nodes within about three months of diagnosis, unless you are having chemotherapy first, because studies have shown better survival when node surgery is done early rather than after nodes become obvious during surveillance.

You may also hear about treatment of PeIN (penile intraepithelial neoplasia, abnormal cells confined to the top layer of skin, also called carcinoma in situ). This is not invasive cancer, and it is treated differently, usually with creams, laser, or a shallow surgery. It still needs treating, because despite treatment, PeIN progresses to invasive cancer in 2.6% to 13% of men.

Surgery

Surgery is the most common treatment for every stage of penile cancer. The operations range from removing a small patch of skin to removing the whole penis, and the choice depends on how deep the tumour goes and where it sits. Surgeons work to a margin, meaning a rim of normal-looking tissue removed around the tumour. Studies show most penile cancers do not extend more than 3/16 inch beyond what the surgeon can see, and a margin of 3/16t nches to 5/8 inches gives acceptably low recurrence rates.

Sometimes the pathologist checks the edges while you are still asleep, using a technique called frozen section. In one UK series of 169 men, using frozen section during organ sparing surgery left only 0.6% with a truly positive margin and a local recurrence rate of 5.3%. Other large series achieved recurrence rates around 4% without using it routinely. Guidelines call it a helpful tool when there is doubt rather than something needed in every case.

Here are the operations you are most likely to hear about for the tumour itself:

• Circumcision: Surgery to remove part or all of the foreskin. Because most PeIN sits on the moist surfaces of the glans or foreskin, circumcision is the first surgical option for PeIN, and after it the skin of the glans toughens over three to six months, which can make residual abnormal areas resolve on their own. For a small cancer on the foreskin, circumcision alone is often the complete treatment. It also makes future examinations and follow-up much easier.

• Wide local excision: Removal of the cancer plus a rim of normal-appearing skin around it, including any red area surrounding the tumour. It suits small lesions on the glans or the ridge behind it. There is not much published data on wide local excision by itself, because it is usually reported inside mixed series of organ-sparing operations, but in studies comparing sexual function it performed better than glansectomy across every domain measured.

• Laser surgery: A narrow beam of intense light used as a bloodless knife. Two lasers are used. The carbon dioxide laser cuts precisely but penetrates less than 1 mm, so it is used to resect the lesion. The Nd:YAG laser penetrates 4 mm to 6 mm and gives deeper, more even sealing of the tumour bed. Healing after carbon dioxide laser is fastest, with the surface skin nearly regrown in three to six weeks, while Nd:YAG can take up to six weeks. For PeIN, laser gives complete response rates of 52% to 100% with recurrence in 7% to 48%. For invasive T1 disease, pooled five-year recurrence-free rates averaged 69.4%, and the penis was preserved in an average of 89.2% of men, which also means a meaningful share of recurrences ended up needing amputation. That is why guidelines suggest laser is best kept to the earliest tumours. Narrowing of the urinary opening occurred in 7.4% and bleeding afterward in 1% to 7%.

• Mohs surgery: The tumour is shaved off in very thin layers, and each layer is examined under a microscope during the operation until no cancer cells remain. It spares the most normal tissue of any technique. Across three studies of 51 men, mostly T1 disease, five-year recurrence-free rates ran from 71.4% to 100%, averaging 88.2%. Because the data are so limited, guidelines do not recommend it routinely and advise involving a clinician experienced in penile cancer before referral.

(Source: National Cancer Institute)

• Cryosurgery: An instrument is used to freeze and destroy the abnormal tissue, also called cryotherapy. Only limited data exist for its use in PeIN, so it is not a mainstream choice, though it is sometimes used for small surface lesions.

• Glans resurfacing: The full thickness of the skin covering the head of the penis is removed and replaced with a graft, usually a thin layer of skin taken from the thigh. Grafts take well here because the wound bed has a good blood supply. For PeIN, recurrence is 0% to 20% and as low as 4% in the guideline summary, and cosmetic results are generally acceptable. For invasive T1 tumours, recurrence-free rates ran from 75% to 96.6%. One important finding: in men resurfaced for presumed PeIN, up to 20% turned out to have invasive cancer once the whole specimen was examined, so this operation is diagnostic as well as therapeutic. Preserving the ridge behind the glans helps keep sensation.

• Glansectomy: Removal of the head of the penis, usually followed by building a new glans from a skin graft. It is the right operation when the tumour is confined to the glans and foreskin but is too big or too deep for excision or resurfacing. In six studies covering 1,681 men, 86.4% with T1 or T2 disease, five-year recurrence-free rates ran from 78.0% to 95.8%. Graft loss occurred in 1.5% to 23.5%, and narrowing of the urinary opening in 2.8% to 14.3%. Cosmetic results were rated good in 95% to 100% of cases, and normal erections were reported in 50% to 100%. Men with poor circulation, diabetes, a suppressed immune system, or previous radiation to the groin are less suitable for grafts because failure rates are higher.

• Partial penectomy: Removal of part of the penis, typically the front portion, leaving enough shaft to pass urine standing and to have penetrative sex. It is the standard operation when the tumour clearly invades the erectile chambers, and it is also an entirely reasonable choice for earlier tumours in men who prefer a wider resection or who do not want the strict follow-up that organ sparing surgery requires. Across five studies of 243 patients, five-year recurrence-free rates ran from 75.8% to 95.4%, averaging 83.9%. Reconstruction can be offered, including centralizing the urinary opening and forming a new glans with a graft.

• Total penectomy with perineal urethrostomy: Removal of the whole penis, with the urethra brought out through a new opening in the perineum, the area between the scrotum and the anus. This is reserved for large tumours where a safe margin would leave a man unable to urinate standing without wetting himself. Urinary control is preserved, because the muscle that holds urine sits deeper inside the body, but urination is done sitting down. Total phallic reconstruction, sometimes called phalloplasty, can be offered afterward. It is a long operation performed at only a few centres, most often using tissue from the forearm, and if nerves and blood vessels can be reconnected, some sensation and the ability to have sex may be possible.

• Lymph node surgery: Separate operations on the groin, described below.

Sentinel lymph node biopsy is the way to check the groin without removing all the nodes. A sentinel node is the first node that fluid from the tumour drains into, so if it is clean, the rest of that group is very likely clean too. In penile cancer, the technique is called dynamic sentinel node biopsy. A tiny amount of radioactive tracer and often a blue dye are injected near the tumour, imaging maps where the fluid actually goes in your body, and the surgeon removes just the node or nodes that light up through a small cut. Sentinel nodes tend to sit in the upper inner part of the groin. If the sentinel node is clear, you avoid the bigger operation. If it contains cancer, the remaining nodes on that side are removed. Where dynamic sentinel node biopsy is not available or not suitable, a lymph node dissection is offered instead.

Inguinal lymph node dissection, or ILND, is surgery to remove the lymph nodes from one or both groins. It is both the most accurate way to know what is in the nodes and the treatment when cancer is already there. Radical ILND remains the standard when nodes are known to be involved. Newer fascial sparing versions leave more supporting tissue behind and reported a three-year disease-free survival of 92.1% with a complication rate of 29.3% in one series of 201 procedures, and a three-year cancer-specific survival of 86% for single node disease in a multicentre series of 421 patients. Surgeons try to spare the saphenous vein, a large vein in the leg, whenever possible, because that lowers swelling afterward.

Be prepared for the fact that groin node surgery has a high complication rate. Contemporary series report that 21% to 55% of men have some complication. The most common are wound infection in 2% to 43%, skin breakdown in 3% to 50%, lymphoedema (fluid buildup and swelling when lymph channels are cut) in 3.1% to 30%, a pocket of lymph fluid called a lymphocele in 1.8% to 26%, and a fluid collection called a seroma in 2.4% to 60%. Most of these are minor and manageable, and at experienced centres serious complications occur in fewer than one man in ten. Video-assisted and robotic approaches through small incisions cut wound problems substantially, with one meta-analysis of 16 comparative studies and 1,054 men finding fewer minor and major complications, fewer wound infections, and a hospital stay about four days shorter. EAU guidelines currently ask that these minimally invasive approaches be used within a clinical trial for known node disease, and not at all for bulky groin disease.

Pelvic lymph node dissection removes nodes deeper inside the pelvis. It is offered when the pathology from the groin shows three or more involved nodes on one side, or shows cancer breaking through the outer capsule of a node, which is called extranodal extension. Those two findings raise the chance of pelvic node cancer sharply, from under 7% to somewhere between a third and two thirds of men. In one series of 89 men, open pelvic dissection had an overall complication rate of 18%.

Recovery from penile surgery varies a great deal by operation. After glansectomy, a urinary catheter usually stays in for about a week and is removed at a follow-up visit, and most men can then urinate normally and have penetrative sex, though sensation is usually different. Grafts need time and protection to take. After groin surgery, drains stay in until fluid output settles, and you will be asked to watch the wound closely. Ask your team for specific timelines about lifting, driving, returning to work, showering, and resuming sex, because those answers depend on the exact operation you have.

Radiation Therapy

Radiation therapy uses high-energy X-rays or other radiation to kill cancer cells or stop them growing. In penile cancer, it has three jobs. It can treat the tumour itself as an alternative to surgery, preserving the penis. It can treat the groin and pelvic nodes after node surgery to lower the chance of the cancer returning there. And it can relieve symptoms in advanced disease.

• External beam radiation therapy: uses a machine outside the body to aim radiation at the area with cancer. You lie still on a table for a few minutes per session, and treatment is usually given daily over several weeks. When it is used on the tumour itself, guidelines call for a minimum dose equivalent to 60 Gy, often with a brachytherapy boost. Treatment planning for large tumours is complex and usually involves custom positioning supports to keep the radiation away from the testicles and scrotum. When external beam radiation is used for locally advanced tumours, guidelines advise giving chemotherapy at the same time.

• Brachytherapy: also called internal radiation therapy, places a radioactive source directly into or right next to the tumour using needles, seeds, wires, or small tubes. Because the source sits so close to the target, high doses reach the cancer while nearby tissue is spared. Brachytherapy has only been studied in tumours under 4 cm, so its use is limited to lesions that size or smaller, and circumcision is usually done first. Results are the best of any radiation approach, with local control of 70% to 90%. Across 21 studies including 1,222 men, the pooled five-year recurrence-free rate was 78.6% after brachytherapy compared with 55.2% after external beam radiation alone. The penis was preserved in 87% of men at five years and 70% at ten years.

Radiation is an especially good option when you want to keep the penis, when surgery is not possible, or when you do not want an operation. A meta-analysis comparing surgery with brachytherapy found five-year overall survival and local control of 76% to 84% for surgery and 73% to 79% for brachytherapy, with no difference in survival and an organ preservation rate of 74% for brachytherapy. Importantly, if the cancer comes back in the penis after radiation, surgery can usually still cure it.

Side effects of radiation to the penis are worth knowing about in advance. Narrowing of the urethra occurs in 20% to 35%, and tissue breakdown of the glans in 10% to 20%, along with late scarring of the erectile chambers. Narrowing of the urinary opening was reported in up to 40% of men in older series but only 6.6% in a recent series of 73 patients, in which 2.6% reported pain with intercourse and 5.3% had burning on urination over five years of follow-up. Amputation because of tissue breakdown was needed in 6.8% in one series. Skin in the treated area can become red, sore, and later thinner or darker. Fatigue is common during a course of treatment.

Sexual function after radiation is often better than men expect. In one report, 17 of 18 men with normal erections before treatment still had them afterward. Among men who were sexually active before brachytherapy, 58.8% to 70% remained sexually active afterward, and potency was maintained in 81.5% to 100%. Altered sensation in the glans was reported by 52.6%. In a group followed for a median of nearly six years, 30% had needed the urethra stretched and 13% were using a catheter themselves, yet erectile problems were mild, and 70% were still sexually active with good quality of life.

When radiation is given to the nodes after surgery, higher doses matter. Guideline evidence states that improving disease-specific and recurrence-free survival in penile cancer requires 54 Gy where cancer has broken through a node capsule and 57 Gy to 60 Gy where cancer remains at the margin. Series using only 50 Gy saw a high rate of the cancer returning inside the treated area. Radiation is also strongly recommended for symptom control in advanced disease, tailored to the specific problem, such as fixed ulcerated nodes or cancer spreading through skin lymph channels.

Chemotherapy

Chemotherapy uses drugs to kill cancer cells or stop them dividing. In penile cancer, it is given in two completely different ways, and mixing them up causes a lot of confusion.

• Topical chemotherapy: a cream you apply to the skin, and it only treats cells right at the surface.

  • Topical chemotherapy with 5-fluorouracil, usually shortened to 5-FU, is used for stage 0 penile cancer and PeIN. Response rates run from 48% to 74%, with recurrence around 11%. Expect the treated skin to become quite red, raw, and crusted for a month or more. That reaction is the treatment working, but it is uncomfortable enough that some men stop early, and about 12% of men on topical treatment discontinue because of side effects.

• Systemic chemotherapy: given into a vein or taken by mouth, travels in the bloodstream, and can reach cancer cells anywhere in the body. It is used when the cancer is too large to remove, has reached the lymph nodes, or has spread to other parts of the body. The backbone is platinum-based treatment, meaning combinations of drugs called cisplatin or carboplatin. You may hear regimens referred to by initials. TIP combines paclitaxel, ifosfamide, and cisplatin. TPF combines docetaxel, cisplatin, and 5-fluorouracil. PF is cisplatin plus 5-fluorouracil. Paclitaxel plus carboplatin is a gentler two-drug option.

• Neoadjuvant chemotherapy: means chemotherapy given before node surgery. It is a reasonable strategy for men with bulky or fixed groin nodes. A systematic review found tumours shrank on imaging in about 53% of men, and about 12.8% had no cancer left in the specimen at surgery. Guidelines favour a cisplatin and taxane-based combination before surgery, and surgery generally follows five to eight weeks after chemotherapy ends.

• Adjuvant Chemotherapy: Chemotherapy after node surgery is more debated. Some studies of men with cancer in pelvic nodes showed better survival with it, while a meta-analysis of four studies covering 771 men found no survival difference compared with observation.

• Chemoradiation means chemotherapy and radiation given together, so the drugs make the cancer more sensitive to the radiation. For locally advanced penile cancer, this is a recognized option, both before surgery and as the definitive treatment when surgery is not wanted or not possible.

Topical and Local Therapy for Precancer

If your biopsy showed PeIN or carcinoma in situ rather than invasive cancer, your treatment options are gentler and mostly do not involve removing part of the penis. The abnormal cells sit in the top layer of skin only. The aim is to clear them, confirm they are gone, and keep watching, because untreated or persistent PeIN progresses to invasive cancer in 2.6% to 13% of men, with a median time to progression of about 13 months in one study.

Circumcision usually comes first when the abnormal area involves the foreskin or sits under it. Beyond removing affected tissue in one piece, it changes the environment. After circumcision, the skin of the glans keratinises, meaning it toughens like ordinary skin, over three to six months, and residual PeIN or the inflammatory skin condition lichen sclerosus may settle on its own. Circumcision also makes creams, laser, and later examinations easier and more reliable.

• Imiquimod: a cream that works through your immune system rather than by killing cells directly. It switches on immune receptors in the skin, creating a controlled inflammatory reaction that clears abnormal cells.

• 5-fluorouracil: a cream, described in the chemotherapy section above, is the other main topical option, with response rates of 48% to 74% and recurrence around 11%.

Both creams cause visible reactions, including redness, swelling, raw areas, ulceration, and crusting, and the reaction varies a lot between men. About 12% of men stop topical treatment because of side effects. It helps enormously to know in advance that the area will look worse before it looks better, and to have a phone number for the team when you are not sure whether what you see is normal.

Laser ablation with a carbon dioxide or Nd:YAG laser is recommended as an option for biopsy-confirmed PeIN as well as for the earliest invasive tumours, with complete response of 52% to 100%. Glans resurfacing with a graft is the more definitive option, with recurrence as low as 4% in the guideline summary, and it has the advantage of sending the entire affected surface to the laboratory, which is how up to 20% of men presumed to have PeIN are found to have invasive cancer. Photodynamic therapy, which uses a light-activated drug, and cryotherapy have only limited data in PeIN.

After any of these treatments, your team will let the area settle for a while and then reassess it, and will biopsy again if there is any doubt. Guidelines are explicit that if topical treatment fails, it should not simply be repeated. A poor response or an early recurrence can be the first sign of invasive disease underneath, and the right response is a fresh biopsy and a rethink of the plan. If the margin of a removed PeIN area comes back positive, watching closely with or without a cream is often more sensible than cutting again, since more surgery there can cost function without much gain.

Immunotherapy and Targeted Therapy

This is the area where the honest answer is that most of it is not standard care yet. Immunotherapy helps your own immune system recognize and attack cancer. Targeted therapy uses drugs aimed at a specific feature of the cancer cell. Both are promising in penile cancer, and both are mostly being tested in clinical trials rather than offered routinely.

• Imiquimod cream: The standard immunotherapy that is a topical one. Applied to the skin for PeIN and carcinoma in situ, it is listed by the National Cancer Institute as an immunotherapy used to treat penile cancer. That is a very different thing from the intravenous immunotherapy drugs you may have read about for other cancers.

• Checkpoint inhibitors: the drugs most people mean by immunotherapy. They release a brake that cancer cells use to hide from immune cells. Penile squamous cell cancers often carry PD-L1, one of the proteins these drugs target, which is why they have been tested. Results so far are modest.

• EGFR-directed therapy targets the epidermal growth factor receptor, a protein on the surface of many squamous cell cancers that drives growth. Several EGFR inhibitors have shown occasional activity in small studies and case series. Dacomitinib, a pill that blocks EGFR and related receptors, produced a 32.1% response rate in a phase 2 study of 28 men with locally advanced or metastatic disease, including one complete response. Nimotuzumab, an antibody against EGFR, was combined with immunotherapy and three-drug chemotherapy before surgery in a Chinese study of 29 men, and of the 24 who had surgery, 14 had no cancer left in the specimen, with two-year overall survival of 72.4%. Those results are encouraging, but no one can yet say which part of that combination did the work, and no EGFR drug is standard treatment for penile cancer.

• HPV directed approaches are the newest frontier. Because roughly half of penile cancers worldwide are linked to high-risk human papillomavirus, especially HPV 16, researchers are testing therapeutic HPV vaccines designed to teach the immune system to attack HPV infected cancer cells, along with adoptive T cell therapy, in which immune cells are collected, modified or expanded in a laboratory, and given back. These are investigational. If you have HPV-linked disease, ask whether any HPV directed trial fits your situation. You can read more about the virus itself in our guide to risk factors for penile cancer.

There are two situations where a targeted drug may be available outside a penile cancer trial. Some countries approve drugs based on a molecular feature regardless of where the cancer started, such as pembrolizumab or dostarlimab for tumours with mismatch repair deficiency or a high mutation count, or trastuzumab deruxtecan for HER2-positive solid tumours. Whether those apply to you depends on genomic testing of your tumour and on the rules where you live. Otherwise, current guidelines state plainly that no data support the routine use of targeted agents in this disease, and that trial enrolment is preferred. Our guide to joining a clinical trial for penile cancer walks through how that works.

Side Effects and Life After Penile Cancer Treatment

Treatment for penile cancer affects parts of life that men are often not used to discussing. You deserve straight information about all of it, and you deserve to know that help exists for every item on this list. Guidelines make it a strong recommendation that your team discusses the effect of treatment on penile appearance, sensation, urination, and sexual function with you beforehand, so you are prepared. Many men say afterward that better information in advance would not have changed their decision, but would have changed how they coped.

• Urinary function changes for most men, though not always for the worse. Some men arrive at treatment already struggling to pass urine because the tumour is blocking the way, and already sitting down to avoid spraying, and for them flow often improves after surgery. What tends to be hardest afterward is spraying and needing to sit or use a bottle or funnel.

• Sexual function is preserved far more often than men fear, especially with organ-sparing surgery. The guideline summary states that penile preserving surgery generally preserves erectile function, though sensation in the glans and the experience of orgasm can change, and that partial penectomy is associated with poorer sexual outcomes overall.

• Body image and identity take a real hit, and pretending otherwise helps no one. Reported concerns center on scarring, change in shape or size, loss of part or all of the penis, no longer urinating standing, and erectile difficulty.

• Penile reconstruction and phalloplasty are genuine options, not consolation prizes. After glansectomy, a new glans is usually built from a thin skin graft. After partial penectomy, the urinary opening can be centralized and a new glans formed. After total or near-total removal, total phallic reconstruction can be offered. It is a long operation, up to about ten hours, performed at only a few hospitals, most commonly using skin from the forearm, and where nerves and blood vessels can be reconnected, some sensation and the ability to have sex become possible.

• Lymphoedema after node surgery is swelling caused by lymph fluid that can no longer drain properly, and it can affect the legs, the scrotum, the penile shaft, the lower abdomen, and the pubic area. It is recommended to be assessed for swelling at every follow-up visit and be referred to a specialist lymphoedema service early, ideally before significant swelling develops. Management includes careful skin care, compression, exercise, massage, and elevating the legs when resting. Specialist services provide made-to-measure compression garments, multilayer bandaging, and scrotal garments that both compress and lift to help drainage.

• Fertility is a separate question from sexual function, and it is easy to overlook in the rush of a cancer diagnosis. Chemotherapy and radiation can lower sperm counts, usually temporarily, and recovery can take up to two years. Radiation aimed near the groin can affect the testicles, and treatment planning often includes positioning designed to spare them. Surgery on the penis does not stop sperm production, but total penectomy changes how semen leaves the body. If you might want biological children, ask about sperm banking before treatment starts.

Finally, none of these effects are things you should try to manage alone. Ask directly who on the team handles sexual function, who handles swelling, and who handles the emotional side. Our guides to penile cancer support and questions to ask about penile cancer can help you start those conversations.

Supportive and Palliative Care for Penile Cancer

Palliative care is care aimed at improving quality of life for people with a serious illness. It treats symptoms and side effects and the psychological, social, and spiritual problems that come with them. The National Cancer Institute is clear that it can be given with or without curative care, that it treats the whole person rather than the disease, and that anyone can receive it regardless of age or stage. It is delivered in hospitals, outpatient clinics, long-term care facilities, and at home.

The most important thing to understand is that palliative care is not hospice. Palliative care can begin at any point, including the day you are diagnosed, and you keep receiving cancer treatment while you have it. Hospice care begins when cure or control of the disease is no longer the goal and the whole focus becomes comfort and support. In the United States, hospice requires certification by two doctors that life expectancy is six months or less, though it can be continued beyond that, and a person can stop hospice at any time. NCI guidance says palliative care should begin when cancer is diagnosed. Research supports this. Studies of integrating palliative care early after a diagnosis of advanced cancer have shown better quality of life and mood, and possibly longer survival, and the American Society of Clinical Oncology recommends that everyone with advanced cancer receive palliative care.

Palliative care in penile cancer covers a specific set of problems, and none of them should be endured quietly:

• Pain management: Pain from the tumour, from node disease, or after surgery is treatable, and there is a whole ladder of options from simple medicines to nerve blocks. Radiation is strongly recommended for symptom control in advanced disease and can be tailored to the exact problem, including fixed ulcerated groin nodes and cancer spreading through skin lymph channels. Retreatment is sometimes needed.

• Wound and odour care: Advanced local disease can produce an open, discharging, and foul-smelling area, and this is one of the most distressing symptoms in penile cancer. It is also one of the most manageable. Specialist nurses have dressings, topical agents, and antibiotics that control smell and discharge, and EAU guidelines call for early involvement of palliative care services for exactly these symptoms. Please tell your team. Embarrassment is the main reason men live with this longer than they need to.

• Lymphoedema therapy: Certified lymphoedema therapists provide compression garments, bandaging, manual lymphatic drainage, exercise programmes, and skin care advice. Referral before significant swelling develops is the guideline recommendation.

• Mental health support: Access to psychological support, counselling, and psychosexual therapy is described in the guidelines as a critical part of survivorship care, and offering it is a strong recommendation. Useful topics include identity and self-esteem, feeling like a burden, beliefs about the illness, the quality of your relationships, body image, and fears about dying.

• Sexual health counselling: A sex therapist or psychosexual therapist is a named member of the recommended penile cancer team. Bring your partner if you have one and if they are willing.

• Nutrition: A registered dietitian can help with appetite loss, weight loss, taste changes, and eating through chemotherapy or radiation. Dietitians are standard members of palliative care teams.

• Social work and financial navigation: Social workers and hospital financial counsellors can help with insurance questions, employment concerns, travel and lodging costs, payment plans, reduced rates, and charity assistance. Financial hardship from cancer is common enough to have its own name, financial toxicity, and there are organizations that help with medicine costs, travel, and living expenses.

Getting palliative care usually starts with asking your oncologist or anyone on the cancer team, who can refer you to a palliative care specialist. Private insurance usually covers palliative care services, Medicare Part B pays for some symptom management services, and Medicaid coverage varies by state. If you are unsure about your coverage, a hospital social worker or financial counsellor is the person to ask.

There is one structural point worth naming. Large volume penile cancer centres are the ones most likely to have specialist nursing, psychological services, and dedicated lymphoedema care in-house, and even in centralized health systems these services vary. If your treating hospital does not have them, ask whether you can be referred for those specific services even while having your routine care locally. Needing to travel is a genuine burden, and video consultations and outreach clinics can reduce it.

Follow-Up Care After Treatment Ends

Follow-up after penile cancer has two purposes. The first is finding a recurrence early, while it can still be cured. The second is looking after you, checking for swelling, urinary and sexual problems, and the emotional aftermath, and connecting you with the right services. Both matter, and it is fair to bring non-cancer concerns to a follow-up visit.

The schedule is front-loaded because the risk is front-loaded. Local and regional recurrences usually happen within the first two to three years. After five years, essentially all new findings were either local recurrences or brand new tumours. That pattern is why guidelines recommend intensive follow-up for the first two years, then less frequent visits, for a minimum of five years total.

Checking yourself is a real part of the plan, not a fallback. Local recurrence is usually easy to see or feel, which is why patient education is essential, and men should be urged to contact a specialist about any change rather than waiting for the next appointment.

Ask for a survivorship care plan when active treatment ends. It has two parts. A written treatment summary records your diagnosis date, cancer type, pathology reports, every surgery with dates, radiation sites and total doses, drug names and doses, key scan and laboratory results, problems you had, and contact details for everyone who treated you. A follow-up care plan lists your visit schedule, the tests you need, the symptoms to watch for, the long-term and late effects to be aware of, and your emotional, social, and financial needs. Late effects can appear months or years after treatment, which is why the written record matters, especially if you move or change doctors.

Contact your care team between visits, without waiting, if you notice a new growth, sore, lump, or colour change on the penis or in the surgical area, swelling of the penis, a new lump or swelling in the groin, new or worsening swelling in a leg or the scrotum, redness and warmth of the skin that could be infection, fever, difficulty passing urine or a much weaker stream, bleeding, a new discharge or smell, unexplained weight loss, new bone pain, or persistent low mood or anxiety. None of these automatically mean the cancer is back. All of them are worth a phone call. You can also create a HealthTree account and electronically download all your records to your phone, which provides a very easy-to-read personal Health Record that you easily be shared with any doctor using a QR code. Connect Medical Records to HealthTree

For context on what these numbers mean over time, see our guide to penile cancer survival rates, and for how your stage was determined in the first place, see our guides to penile cancer stages and how penile cancer is diagnosed. Whatever your situation, the next step is a conversation with your own care team about what these options mean for you and what you want to do.

Sources:

• Penile Cancer Treatment, National Cancer Institute

• Treatments for Penile Cancer, Canadian Cancer Society

• Surgery for Penile Cancer, Canadian Cancer Society

• Follow-up After Treatment for Penile Cancer, Canadian Cancer Society

• Palliative Care in Cancer, National Cancer Institute

• Choices for Care with Advanced Cancer, National Cancer Institute

• Lymphedema and Cancer, National Cancer Institute

• Sexual Health Issues in Men with Cancer, National Cancer Institute

• Male Fertility and Cancer Treatment, National Cancer Institute

• Follow-Up Medical Care After Cancer Treatment, National Cancer Institute

• Cancer Survivorship, National Cancer Institute

• Sentinel Lymph Node Biopsy, National Cancer Institute

• Managing Cancer Costs and Medical Information, National Cancer Institute